{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:25:04Z","timestamp":1775748304867,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The objective of the present study was to evaluate the prognostic impact of the upper urinary tract cancer status on recurrence-free survival and progression-free survival, and to develop risk stratification systems that include the upper urinary tract cancer status for patients with non-muscle invasive bladder cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>The present study included 40 (upper urinary tract cancer-non-muscle invasive bladder cancer group) and 285 (non-muscle invasive bladder cancer alone group) patients with and without a history of prior or concomitant upper urinary tract cancer, respectively. Nine clinicopathological findings between the two groups were compared, and risk stratification systems for the recurrence and progression of non-muscle invasive bladder cancer were developed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Recurrence-free survival and progression-free survival in the upper urinary tract cancer-non-muscle invasive bladder cancer group were significantly inferior to those in the NMIBC alone group (P\u00a0&amp;lt;\u00a00.001 and P\u00a0=\u00a00.006, respectively). Multivariate analyses identified the following independent prognosticators: multiplicity and upper urinary tract cancer status for recurrence-free survival, and pT category and upper urinary tract cancer status for progression-free survival. Significant differences were noted by the risk stratification systems based on the positive number of independent predictors of recurrence-free survival and progression-free survival (P\u00a0&amp;lt;\u00a00.001 and P\u00a0=\u00a00.007, respectively). The concordance indices of recurrence-free survival were 0.627, 0.588 and 0.499 in this study stratification, EORTC risk table and CUETO model, respectively. Those of progression-free survival were 0.752, 0.740 and 0.714, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The present results suggest the significant impact of a history of prior or concomitant UUTC on recurrence-free survival and progression-free survival in non-muscle invasive bladder cancer patients, and risk stratification systems that include the upper urinary tract cancer status for the recurrence and progression of non-muscle invasive bladder cancer are promising tools for predicting the outcomes of these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyac068","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:18:22Z","timestamp":1649935102000},"page":"944-949","source":"Crossref","is-referenced-by-count":1,"title":["Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-9793","authenticated-orcid":false,"given":"Yuto","family":"Matsushita","sequence":"first","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1340-4739","authenticated-orcid":false,"given":"Ryo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1171-9948","authenticated-orcid":false,"given":"Kyohei","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-7328","authenticated-orcid":false,"given":"Keita","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Motoyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"key":"2022093018321091700_ref1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1464-410X.2005.05804.x","article-title":"Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology","volume":"96","author":"Raman","year":"2005","journal-title":"BJU Int"},{"key":"2022093018321091700_ref2","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.juro.2013.01.024","article-title":"Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"189","author":"Hagiwara","year":"2013","journal-title":"J Urol"},{"key":"2022093018321091700_ref3","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.urolonc.2012.03.004","article-title":"Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma","volume":"31","author":"Milojevic","year":"2013","journal-title":"Urol Oncol"},{"key":"2022093018321091700_ref4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urolonc.2009.06.003","article-title":"Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance","volume":"29","author":"Azemar","year":"2011","journal-title":"Urol Oncol"},{"key":"2022093018321091700_ref5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","article-title":"A systematic review and meta-analysis of clinicopathologic factors linked to Intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma","volume":"67","author":"Seisen","year":"2015","journal-title":"Eur Urol"},{"key":"2022093018321091700_ref6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/iju.14103","article-title":"Impact of post-void residual urine volume on intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma","volume":"26","author":"Sazuka","year":"2019","journal-title":"Int J Urol"},{"key":"2022093018321091700_ref7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/iju.14014","article-title":"Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma","volume":"26","author":"Yamamoto","year":"2019","journal-title":"Int J Urol"},{"key":"2022093018321091700_ref8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"key":"2022093018321091700_ref9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(05)67137-6","article-title":"Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"2022093018321091700_ref10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bju.13935","article-title":"Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis","volume":"120","author":"Marchioni","year":"2017","journal-title":"BJU Int"},{"key":"2022093018321091700_ref11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.urology.2004.09.021","article-title":"Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract","volume":"65","author":"Matsui","year":"2005","journal-title":"Urology"},{"key":"2022093018321091700_ref12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.12400","article-title":"Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy","volume":"114","author":"Xylinas","year":"2014","journal-title":"BJU Int"},{"key":"2022093018321091700_ref13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bju.14111","article-title":"Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma","volume":"121","author":"Miyake","year":"2018","journal-title":"BJU Int"},{"key":"2022093018321091700_ref14","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00345-018-2581-3","article-title":"Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system","volume":"37","author":"Kim","year":"2019","journal-title":"World J Urol"},{"key":"2022093018321091700_ref15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/iju.14657","article-title":"Therapeutic options to reduce intravesical recurrence in newly diagnosed ta high-grade bladder cancer according to risk stratification: a multicenter retrospective study","volume":"28","author":"Shindo","year":"2021","journal-title":"Int J Urol"},{"key":"2022093018321091700_ref16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2022093018321091700_ref17","doi-asserted-by":"crossref","first-page":"78 e71","DOI":"10.1016\/j.urolonc.2020.08.029","article-title":"Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy","volume":"39","author":"Tamura","year":"2021","journal-title":"Urol Oncol"},{"key":"2022093018321091700_ref18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"2022093018321091700_ref19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"2022093018321091700_ref20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.eururo.2016.09.046","article-title":"Mutagenic factors and complex clonal relationship of multifocal urothelial cell carcinoma","volume":"71","author":"Du","year":"2017","journal-title":"Eur Urol"},{"key":"2022093018321091700_ref21","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1038\/ncomms4756","article-title":"Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden","volume":"5","author":"Cazier","year":"2014","journal-title":"Nat Commun"},{"key":"2022093018321091700_ref22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1126\/science.aba7300","article-title":"Macroscopic somatic clonal expansion in morphologically normal human urothelium","volume":"370","author":"Li","year":"2020","journal-title":"Science"},{"key":"2022093018321091700_ref23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"2022093018321091700_ref24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.euf.2018.11.005","article-title":"Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel","volume":"6","author":"Soukup","year":"2020","journal-title":"Eur Urol Focus"},{"key":"2022093018321091700_ref25","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1464-410X.2010.09850.x","article-title":"Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines","volume":"107","author":"Sakano","year":"2011","journal-title":"BJU Int"},{"key":"2022093018321091700_ref26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.urology.2013.04.007","article-title":"Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models","volume":"82","author":"Xu","year":"2013","journal-title":"Urology"},{"key":"2022093018321091700_ref27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer","volume":"58","author":"Rhijn","year":"2010","journal-title":"Eur Urol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/8\/944\/46214796\/hyac068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/8\/944\/46214796\/hyac068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T19:49:01Z","timestamp":1664567341000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/8\/944\/6573315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4,23]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac068","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,4,23]]}}}